Fundraising Fox

Vergentbio

Minneapolis, US · 3 known investors

Vergent Bioscience is a clinical-stage biotechnology company developing abenacianine (VGT-309), a tumor-targeted fluorescent imaging agent that helps surgeons see tumors in real time during minimally invasive and robotic-assisted surgery. Its lead compound is first being evaluated in lung cancer, with potential expansion to other solid tumors.

BiotechHealthtechMedical Devices

Founders & leadership

JJ
Jeff JulkowskiNamed on SEC filing
DK
Douglas KohrsNamed on SEC filing
RW
Raymond WongNamed on SEC filing
JY
Jeffrey YureckoNamed on SEC filing
JS
John SantiniNamed on SEC filing
AW
Anita WatkinsNamed on SEC filing
SD
Samuel Dean BanksNamed on SEC filing
RE
Ryan EgelandNamed on SEC filing
BH
Bobby HelmedagNamed on SEC filing

Investors · 3

Colle Capital PartnersNew York · $500K – $2M
Windham Capital PartnersNew York · $1M – $5M
Spring Mountain CapitalreportedNew York

Reported raises · per SEC filings

Form D private placements

$57M disclosed across 5 of 6 rounds · 2018–2025

▶$18.7MraisedOct 2025 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bobby HelmedagDirector
  • Jeffrey YureckoExecutive Officer
  • Anita WatkinsDirector
  • John T. Santini, Jr.Executive Officer, Director
  • Raymond WongDirector
  • Douglas KohrsDirector
Offering amount
$32M
Amount sold
$18.7M
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.8MraisedFeb 2025 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeff JulkowskiDirector
  • Douglas KohrsDirector
  • Raymond WongDirector
  • Jeffrey YureckoExecutive Officer
  • John SantiniExecutive Officer, Director
  • Anita WatkinsDirector
  • Samuel Dean BanksDirector
  • Ryan EgelandDirector
  • Bobby HelmedagDirector
Offering amount
$5M
Amount sold
$3.8M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$21.5MraisedOct 2022 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ryan EgelandDirector
  • John SantiniExecutive Officer, Director
  • Margo ShoupDirector
  • Douglas KohrsDirector
  • Jeffrey YureckoExecutive Officer
  • Raymond WongDirector
  • Jeffrey JulkowskiDirector, Promoter
  • Samuel BanksDirector
Offering amount
$22.1M
Amount sold
$21.5M
First sale
Aug 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedNov 2021 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey JulkowskiDirector, Promoter
  • Raymond WongDirector
  • John SantiniExecutive Officer, Director
  • Ryan EgelandDirector
  • Samuel Dean BanksDirector
  • Douglas KohrsDirector
  • Jeffrey YureckoExecutive Officer
Offering amount
$2M
Amount sold
$1.2M
First sale
Nov 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.9MraisedSep 2020 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Samuel Dean BanksDirector
  • Douglas KohrsDirector
  • Ryan EgelandDirector
  • John SantiniExecutive Officer, Director
  • Jeffrey JulkowskiDirector, Promoter
  • Jeffrey YureckoExecutive Officer
  • Raymond WongDirector
Offering amount
$11.9M
Amount sold
$11.9M
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$2M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Vergent Bioscience, Inc. has filed a notice of an exempt offering of securities to raise $31,957,273.00 in New Funding. - intelligence360intelligence360.news · Nov 2025Vergent Bioscience raises $21.5 million, reflecting sustained investor interest in life sciencesstartribune.com · Oct 2022Tumor-Spotting Startup Vergent Bioscience Lands $21.5M | Twin Cities Businesstcbmag.com · Oct 2022Vergent Bioscience raises $21.5M in Series B funding - Minneapolis / St. Paul Business Journalbizjournals.com · Oct 2022Stealthy Vergent Bioscience raises $9m for tumor-fluorescing tech - MassDevicemassdevice.com · Jun 2018Vergent Bioscience Raises $8.7 Million in Series A Financing Led by Spring Mountain Capitalprnewswire.com · Jun 2018

Frequently asked questions

What does Vergentbio do?
Vergent Bioscience is a clinical-stage biotechnology company developing abenacianine (VGT-309), a tumor-targeted fluorescent imaging agent that helps surgeons see tumors in real time during minimally invasive and robotic-assisted surgery. Its lead compound is first being evaluated in lung cancer, with potential expansion to other solid tumors.
Who are Vergentbio's investors?
Vergentbio's investors include Colle Capital Partners, Windham Capital Partners, Spring Mountain Capital.
How much funding has Vergentbio raised?
Vergentbio has disclosed $57M raised across 5 of its 6 known rounds.
Where is Vergentbio headquartered?
Vergentbio is headquartered in Minneapolis, US.